Introduction: Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is one of the most frequent inborn conditions. It is caused by distinct mutations in the CYP21A2 gene and in the majority of cases the disease's severity correlates with CYP21A2 allelic variation Our aim was to describe the mutational spectrum of CYP21A2 and evaluate genotype-phenotype correlation in a cohort of portuguese patients with 21-hydroxylase deficiency. Material and Methods: Retrospective study of 22 patients with clinical diagnosis of 21-hydroxylase deficiency. Molecular analysis of CYP21A2 was performed and genotype-phenotype correlation was then established. Results: Genotyping was performed in 22 unrelated patients: 5 with classic salt-wasting (average age of diagnosis 10.2 days; minimum 1, maximum 20 days), 7 with classic simple virilizing (average age of diagnosis 3.5 years; minimum 0 days, maximum 7 years) and 10 with nonclassical form (average age of diagnosis 5.7 years; minimum 4 years, maximum 8 years). The most frequent genetic defects in the classic forms were I2 splice (24%) and I172N (24%), followed by Q318X (16%) and gene deletions (16%) and in the nonclassical form, the V281L (80% Resultados: Foi realizada genotipagem em 22 doentes não relacionados: 5 com a forma clássica perdedora de sal (idade média ao diagnóstico de 10,2 dias; mínimo 1, máximo 20 dias), 7 com a forma clássica virilizante simples (idade média ao diagnóstico de 3,5 anos; mínimo 0 dias, máximo 7 anos) e 10 com a forma não clássica (idade média ao diagnóstico de 5,7 anos; mínimo 4 anos, máximo 8 anos). Os defeitos genéticos mais frequentes nas formas clássicas foram o I2 splice (24%) e I172N (24%), seguindo-se o Q318X (16%) e deleções de genes (16%) e, na forma não clássica, o V281L (80%). Verificou-se uma concordância genótipo-fenótipo global de 81,8%. O genótipo permitiu prever adequadamente o fenótipo em 83,3%, 100% e 90% dos doentes com mutações compatíveis com a forma clássica perdedora de sal, clássica virilizante simples e não clássica, respectivamente. Discussão: A frequência de defeitos genéticos observados nos nossos doentes é comparável a estudos semelhantes. Observou-se, na maioria dos casos, uma boa correlação genótipo-fenótipo. Conclusões: A análise molecular do CYP21A2 fornece informação importante relativamente à gravidade da doença e no aconselhamento genético e pré-natal. Palavras-chave: Esteróide 21-Hidroxílase; Fenótipo; Genótipo; Hiperplasia Congénita Suprarrenal.
INTRODUCTION
Congenital adrenal hyperplasia (CAH) includes a group of autosomal recessive genetic disorders affecting cortisol synthesis. It is one of the most common genetic diseases and approximately 95% of the patients present with 21-hydroxylase (21-OH) enzyme deficiency, 1 an enzyme responsible for the conversion of 17-hydroxyprogesterone (17-OHP) into 11-deoxycortisol, a cortisol precursor and for the conversion of progesterone into deoxy-corticosterone, an aldosterone precursor. 2 CYP21A2 gene encoding 21-OH is located on the short arm of chromosome 6, in close proximity to its pseudogene and highly homologous -CYP21A1P. 3 The mutations responsible for 21-OH deficiency result from intergenic unequal recombination between CYP21A2 and CYP21AP1, a process called gene conversion. 4 Most mutations relate to short sequence transfer from the pseudogene to the CYP21A2 within meiosis. 5 Approximately 75% of the patients are compound heterozygous for mutations that are responsible for the disease and its severity is determined by the activity of the less seriously affected allele which maintains residual 21-OH activity. [6] [7] [8] [9] CAH is ranked into classical and non-classical (NC) forms. Classical CAH is subdivided into salt-wasting (SWCAH) and non-salt wasting, also termed simple virilising CAH (SVCAH).
Classical CAH occurs in around 1 in each 7,000-15,000 births, on most populations. 10 Non-classical CAH incidence is less well-defined, although a prevalence of 1 in each 1,000 births is estimated. 11 In SWCAH, unlike SVCAH, patients are not able to synthesize enough aldosterone in order to keep sodium homeostasis, [6] [7] [8] [9] corresponding to the most severe form of the disease and affecting approximately 75% of the patients presenting with the classical form. 12 Beyond the signs of virilisation and hypocortisolism, the patients present with mineralocorticoid failure, with a tendency for potentially deadly episodes of hypotension, hyponatremic dehydration with hyperkalemia and hypovolemic shock, particularly in newborn infants. [6] [7] [8] [9] 12 The diagnosis is usually early in life in female patients due to the presence of genital virilisation, secondary to androgen excess during pregnancy. In male newborn infants, clinical manifestations are more subtle, involving scrotal and genital hyperpigmentation at birth, feeding difficulties and failure to thrive. Diagnosis may be obtained later, often in the context of an adrenal crisis. [6] [7] [8] [9] 12 CAH presents with signs of prenatal virilisation of external genitalia in females and hypocortisolism and pseudo-precocious puberty in both genders. 11, 12 It may present with accelerated growth and advancement of skeletal maturation, phallic enlargement in boys and clitoromegalia in girls. 7, 11, 12 The milder forms are termed non-classical or late-onset forms. These do not present with neonatal genital virilisation but rather with signs of hyperandrogenism at a later stage. It may present with development of pubic hair, acne and advanced bone age in childhood and with acne, hirsutism and abnormal menstrual cycles in adolescence. It may in fact be asymptomatic in male patients. 11, 12 The elevation of 17-OHP -the main substrate for the enzyme -is the most characteristic biochemical abnormality in 21-OH deficiency. Basal serum 17-OHP values usually exceed 10,000 ng/dL although about 10% of severely affected infants have low initial levels in the newborn period, especially if levels are obtained on the first day of life. Measurements of basal serum 17-OHP significantly increase upon ACTH stimulation (1,500 to 10,000 ng/dL). 12 but levels may be normal or slightly elevated in NC forms.
Several studies analysed the correlation between CYP21A2 genotype and the phenotype 6, 7, 9, 13 and found this to be high (80-90%) although the phenotype may not always be predicted by the genotype. 8, 13, 14 Our study aimed to describe the spectrum of mutations of the CYP21A2 gene in patients with CAH and to assess the genotypic-phenotypic correlation in a group of Portuguese children with 21-OH deficiency.
MATERIAL AND METHODS:
This was a retrospective study involving 22 children with clinical and laboratorial criteria of 21-OH deficiency attending the Endocrinology Department at Porto Hospital Centre between 2000 and 2013.
Molecular testing of CYP21A2 gene was carried out in all the patients, based on DNA obtained from peripheral blood samples. The most common mutations were analysed, as well as deletions/conversions in the CYP21A2 gene: P30L (exon 1), I2 splice (intron 2), I172N (exon 4), V281L (exon 7), Q318X and R356W (exon 8), cluster E6 (exon 6), P453S (exon 10).
Testing did not include the sequencing of the entire gene in patients in whom no mutation was found.
The search for large deletions/conversions in the CYP21A2 gene was based on multiplex ligation-dependent probe amplification (MRC Holland) techniques.
Phenotype classification of patients was established upon a joint review by the three pediatric endocrinologists in our Department, based on clinical and hormonal criteria, through the retrospective analysis of patient's clinical record. In the presence of evident clinical and biochemical signs of adrenal crisis (failure to thrive, hyponatremia, hyperkalemia and high renin level), patients were ranked as presenting with SWCAH. In this group, the level of 17-OHP in the first month of life was > 2,500 ng/dL. The female patients with ambiguous genitalia but no electrolyte imbalance or in whom an early virilisation beyond the neonatal period was detected, were classified as presenting with SVCAH forms.
The boys that developed signs and symptoms of hyperandrogenism, advanced growth or bone age, with high levels of 17-OHP but no evidence of salt wasting were also included in this group of patients. The presence of symptoms of hyperandrogenism in pre-puberty (development of pubic hair, acne, hirsutism, adult body odor and absence of complete genital virilisation) associated to high levels of 17-OHP was used for the diagnosis of patients with nonclassical forms. These patients had levels of 17-OHP ≥ 500 ng/dL.
Classification by mutation group:
The mutations that are responsible for the disease were classified into 4 groups, according to the level of the estimated enzymatic activity for each mutation, based on in vitro studies. 6, 7 Group 0, with null activity, included the patients with mutations on both alleles resulting in the absence of enzyme activity (gene deletions/conversions, Table 1 ∆8bp, F306+t, cluster E6, Q318X, R356W). Group A included patients homozygous for l2 splice mutation or compound heterozygous for I2 splice and null mutation, with minimal enzyme activity (0-1%). Group B included the patients with I172N mutations (with ~2% residual enzyme activity), homozygous or compound heterozygous with groups 0, A or B. Group C included genotypes with a mild mutation in at least one of the V281L, P30L or P453s alleles (~20-60% residual enzyme activity, homozygous or compound heterozygous with group 0, A or B. A fifth group (unclassified) included patients in whom only one mutation in one of the alleles of CYP21A2 was found.
The expected phenotype for group 0 and A is SWCAH, SVCAH for group B patients and NC CAH forms for group C patients.
Based on the patient's genotype, a predicted phenotype was established, according to the enzyme activity (allowed by the less-affected allele) and the degree of concordance between the expected and the observed phenotype was evaluated.
RESULTS
In total, 22 non-related patients diagnosed with CAH due to 21-OH deficiency were genotyped. The molecular defects, as well as clinical and biochemical data are shown in Table 1 All the patients were Caucasian and a clear female predominance (16/22 patients) was found.
The average age at which SWCAH was diagnosed was 10.2 days (minimum 1, maximum, 20 days). As regards SVCAH, only one newborn girl was diagnosed at birth. In the remaining patients the average age was 3.5-years (minimum, 2 years, maximum, 7 years). Non-classical forms were diagnosed at an age average of 5.7-year (minimum, 4 years, maximum, 8 years).
A subsequent 21-OH deficiency diagnosis was found in the brothers (upon family screening) of two patients (patients 16 and 21) (these were not included in the study).
The remaining patients did not show any positive family history. Basal levels of 17-OHP varied between 2,500 and 9,554 ng/dL in classical and between 500 and 4,730 ng/dL in nonclassical forms. In the patients that underwent the ACTH stimulation test the 17-OHP level measured at 60 minutes varied between 1,600 and 8,884 ng/dL.
The frequency of molecular defects found in our group of patients is shown in Table 2 . From the 22 patients, mutations in both alleles were found in 20 patients (90.9%), therefore confirming the genetic diagnosis of the disease. The presence of only one mutation (Q318X and V281L) was found in 2 patients. The most prevalent mutations in the classical form were the I2 splice (24%) and the I172N (24%), followed by the Q318X mutation (16%) and gene deletions (16%). In non-classical forms, V281L was the most frequent mutation (80%).
The type of mutation according to the expected degree of enzyme activity and expected clinical phenotype is shown in Table 3 . Eight patients were homozygous for mutations, 12 were compound heterozygous and 2 were heterozygous for one mutation. A 81.8% genotype-phenotype concordance (18/22 patients) was found, with total concordance in groups A and B where SWCAH and SVAH presentation was expected, respectively. A newborn girl diagnosed on the first day of life with ambiguous genitalia, despite not having presented with salt-wasting signs, was classified as a SWCAH phenotype as she required treatment with mineralocorticoid and salt supplementation. Early diagnosis and treatment were provided to this patient and adrenal crisis was prevented. In group 0, in which SWCAH was expected, one of three patients was discordant (66.7% genotype-phenotype concordance). This was a boy with a mutation consistent with the SWCAH form and with SVCAH clinical manifestations, who was diagnosed at the age of 7 due to the development of signs of puberty and advanced growth, with basal 17-OHP levels of 9,554 ng/dL at the time of diagnosis and stimulated 17-OHP levels of 8,884 ng/dL. A 90% concordance was found in group C (9/10 patients). A discordant patient regarded a boy with a consistent genotype with a NC form and presenting with SWCAH clinical phenotype. This patient presented with precocious pseudo-puberty signs and intensely advanced growth at the age of 4, with a testosterone level of 142 ng/ dL and basal 17-OHP of 4,550 ng/dL.
Two patients, one boy with SWCAH clinical manifestations at the age of 3 and a girl with NC CAH phenotype diagnosed at the age of 7, presented with a single mutation and were expected to have been asymptomatic.
DISCUSSION
Our study describes the mutational spectrum, as well as the allelic frequency and genotype-phenotype correlation regarding a group of Portuguese non-related patients with CAH due to 21-OH deficiency.
All the mutations identified in our patients had been previously recognized 6, 7, 11 , generated by the recombination between the active CYP21 gene and its pseudogene.
In our group of patients, the mutational spectrum was generally in line with that described in several studies. 6, 7, [15] [16] [17] [18] The most prevalent mutations found in the classical forms included the I2 splice (24%) and I172N (24%), followed by the Q318X (16%) and gene deletions (16%). A higher frequency of the Q318X mutation than in most populations was found in our group of patients, also in line with other studies. 19, 20 The V281L mutation was more prevalent in NC forms (80%), in line with other populations, [6] [7] [8] [9] 17, 18, [20] [21] [22] [23] as well as with a previous study involving the Portuguese population. 13 A good genotype-phenotype correlation was found in our study (global correlation of 81.8%) and the genotype allowed for a phenotype prediction in 83.3%, 100% and 90% of the patients with mutations consistent with SWCAH, SVCAH and NC forms, respectively. The groups A and B were those in which a higher concordance was found. This difference regarding other studies 14, [16] [17] [18] [19] [20] [21] 24 (in which a higher concordance was found in the groups at the extremes of severity) may be explained by the reduced size of our group of patients and by the type of mutations found. The observed phenotype was less severe than expected on one patient (patient 12). This was a patient with two null mutations presenting with SWCAH. In such patients, some studies 14, 25 hypothesise that genetic variations in CYP2C19 and CYP3A4, the presence of other enzymes with a capability to modulate the electrolyte balance in patients with CAH or a combination of unknown factors may model these steroid pathways and therefore explain these findings.
In contrast, one of the patients (patient 11) presented with a more severe form than expected by the genotype, with clinical manifestations compatible with SVCAH and a NC-predictor genotype. The high variability of the enzyme activity in the mutation I172N 14 can contribute to the phenotype variability and may explain this patient's diagnosis. The observed discrepancies may also be explained by new mutations that were not searched at the time of diagnosis (and that may explain for the phenotype of the 2 children in whom only one mutation was detected), by incomplete genotyping, by compound heterozygosity for two or more mutations and by other genetic variations in androgen biosynthesis or sensitivity.
In our study we unexpectedly found that more than half of the patients presented with the classical form of the disease (54.5%). 25 This finding may reflect difficulties in diagnosis, as well as an underestimate of the forms with milder clinical presentation 1, 23 or reflect the small size of the group of patients. In addition, the NC form of CAH may present with a variety of symptoms of hyperandrogenism, making a differential diagnosis more difficult, namely with the Polycystic Ovary Syndrome. It should be mentioned that only patients aged below 18 were included in our group of patients and that many NC forms of CAH are diagnosed in adult age related to infertility. 26 A female predominance was also evident, in line with literature. As an autosomic recessive pathology, it should occur equally in both genders. 23 This asymmetry, mainly observed in NC forms, in which all the children presented with a V281L genotype in at least one of the alleles (with a 9:1 female:male proportion) may relate to the fact that boys are often underdiagnosed as signs of hyperandrogenism are less obvious.
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CONCLUSIONS
The knowledge of the ethnic origin of the CYP21A2 mutations is crucial in all CAH forms. The fact that there is a limited number of mutations responsible for most CAH cases, already described in literature and confirmed in our study, makes the detection of mutations useful in prenatal screening. The prenatal diagnosis with the analysis of DNA obtained by amniocentesis or by a chorionic villus biopsy has major therapeutic impact in female gender and prevents external genitalia virilisation and an incorrect gender attribution. In addition, it may anticipate the development of a potentially lethal adrenal crisis and prevent hyperandrogenism in childhood.
Despite some variability in clinical expression, a good correlation of the CYP21A2 genotype with the CAH phenotype was found in most cases. Therefore, our study reinforces the importance of the molecular study of the CYP21A2 as a complementary tool to predict the severity of the disease as well as the importance in genetic and prenatal counselling.
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